Global Biosimilar Market Outlook 2022 - Emerging Markets is an Area of Opportunities for Biosimilars & Patent Expiry of Blockbuster Biologics - Research and Markets

DUBLIN, September 13, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Biosimilar Market Outlook 2022" report to their offering.

The global biosimilars market is anticipated to witness a high double digit growth during 2016-2022

This report provides a detailed analysis of the current and future market scenario of the global biosimilars market. The report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global biosimilars market.

A biosimilar is a biologic product that is similar to a regulatory body approved reference product, and has no clinically meaningful differences in terms of safety and effectiveness from that reference product. Only minor differences in clinically inactive components are allowable in biosimilar products. The global biosimilars market is expected to witness a steep growth owing to the patent expiry of blockbuster biologic drugs. The ability of biosimilars to reduce healthcare costs is another driving factor for this industry. Furthermore, the recent approval of three biosimilars in the US market is providing an impetus to more biopharmaceutical companies to enter this field.

The global biosimilars market has been segmented on the basis of type of product. The major types of biosimilars present in the market include monoclonal antibodies, erythropoietin, insulin, G-CSF, HGH, and interferon amongst others. The report also highlights the various biosimilar drugs available in the market, and the biosimilars currently in various phases of clinical trials.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Global Biosimilars Market Outlook 2022

4. Market Dynamics
4.1 Drivers
4.1.1 Growing Geriatric Population
4.1.2 Entry of Biosimilars in the US Market
4.1.3 Ability to Curb Healthcare Cost
4.1.4 Rising Incidences of Chronic Diseases
4.1.5 Government Initiatives
4.2 Challenges
4.2.1 Regulatory Issues
4.2.2 Greater Litigation Risk
4.2.3 Lack of Standardized Manufacturing Process
4.3 Opportunities
4.3.1 Emerging Markets - Area of Opportunities for Biosimilars
4.3.2 Patent Expiry of Blockbuster Biologics

5. Market Segmentation by Product Type
5.1 Erythropoietin (EPO)
5.2 Human Growth Hormone (HGH)
5.3 Granulocyte- Colony Stimulating Factor (G-CSF)
5.4 Monoclonal Antibody (mAb)
5.5 Insulin
5.6 Interferon (IFN)
5.7 Others

6. Market Segmentation by Geography

7. Market Segmentation by Applications
7.1 Oncology
7.2 Blood Disorders
7.3 Others

8. Market Trends and Developments
8.1 Development of Modular Biosimilar Plants
8.2 Biosimilars in Oncology

9. Mergers and Acquisitions

10. Porter's Five Forces Analysis

11. Competitive Landscape
11.1 Market Share of Major Players
11.2 Company Profiles

12. Future Outlook

Companies Mentioned

• Amgen Inc.
• Biocad
• Biocon
• Celltrion Inc.
• Dong-A Socio Group
• Intas Pharmaceuticals Ltd.
• Pfizer Inc.
• Sandoz International GmbH - A Novartis Company
• Stada Arzneimittel AG
• Teva Pharmaceutical Industries Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/npst2d/global_biosimilar

Related Topics: Biosimilars and Biosuperiors

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call [phone]
For U.S./CAN Toll Free Call [phone]
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]